Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study.

ABSTRACT:

Introduction

The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the cognitive function in patients initiating PCSK9i, and differences in cognitive function domains, to analyze subgroups by the low-density lipoprotein cholesterol (LDL-C) achieved, and differences between alirocumab and evolocumab.

Methods

This has a multicenter, quasi-experimental design carried out in 12 Spanish hospitals from May 2020 to February 2023. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA).

Results

Among 158 patients followed for a median of 99 weeks, 52% were taking evolocumab and 48% alirocumab; the

SUBMITTER: Seijas-Amigo J 

PROVIDER: S-EPMC10462529 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature